UNSPSC 51282903: Amifloxacin

This classification denotes a quinolone antibiotic with the molecular formula C16H19FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TU5227KYQ, chemically known as 6-fluoro-1,4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid but generally known as amifloxacin, which bears US NIH Compound Identifier 55492. Amifloxacin most often comes in mesylate and n-oxide forms.

UNSPSC 51282903 Amifloxacin is a Commodity code representing pharmaceutical products, though recent state and local solicitations under this code show minimal direct activity for amifloxacin itself and instead reflect broader pharmaceutical procurement across multiple product categories—naloxone, generic multi-source drugs, OTC products, and first-aid supplies. State and local governments use codes in this family to procure medications and pharmaceutical products for emergency response, community health programs, pharmacy benefit programs, and departmental medical needs. The issuing bodies soliciting under related pharmaceutical codes include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire and rescue divisions (City of Tampa), and multistate cooperative purchasing alliances (Minnesota MMCAP serving state and local facilities across multiple states including Oregon).

Recent solicitations demonstrate geographic spread across Florida, Texas, Minnesota, and Oregon, with cooperative purchasing mechanisms (MMCAP) spanning multiple jurisdictions. Representative recent opportunities include Seminole County's invitation for bid (IFB) for 1,900 units of naloxone and 800 drug deactivation systems annually, due July 26, 2023; the City of Tampa's sealed-bid solicitation (26P00145) for 169 line items of medical and first-aid supplies for the fire department rescue division, with an estimated contract value of $700,000, due March 13, 2026, designated as a sheltered market opportunity for certified small local business enterprises with a 5 percent bid discount; the Minnesota MMCAP's request for proposal (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; and the Texas HHS Commission's request for information (RFI HHS0017013) exploring direct-to-manufacturer prescription programs, posted April 3, 2026. The code shows little direct activity for amifloxacin specifically; opportunities appear tagged to the broader pharmaceutical family rather than this specific antimicrobial product.